111 Inc
NASDAQ:YI
111 Inc
Cost of Revenue
111 Inc
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
111 Inc
NASDAQ:YI
|
Cost of Revenue
-¥14.1B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
D
|
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
|
Cost of Revenue
-¥16.5B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
LBX Pharmacy Chain JSC
SSE:603883
|
Cost of Revenue
-¥15.2B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
Yunnan Jianzhijia Health-Chain Co Ltd
SSE:605266
|
Cost of Revenue
-¥4.8B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
Cost of Revenue
-¥14.5B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
|
Cost of Revenue
-¥12.3B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
See Also
What is 111 Inc's Cost of Revenue?
Cost of Revenue
-14.1B
CNY
Based on the financial report for Dec 31, 2023, 111 Inc's Cost of Revenue amounts to -14.1B CNY.
What is 111 Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-53%
Over the last year, the Cost of Revenue growth was -11%. The average annual Cost of Revenue growth rates for 111 Inc have been -22% over the past three years , -53% over the past five years .